Elsevier

La Presse Médicale

Volume 42, Issue 10, October 2013, Pages 1317-1330
La Presse Médicale

Recommendations
Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitidesRituximab : recommandations du Groupe français d’étude des vascularites (GFEV) pour son utilisation en traitement d’induction et d’entretien des vascularites nécrosantes associées aux ANCA de l’adulte

https://doi.org/10.1016/j.lpm.2013.08.003Get rights and content

Summary

Increasing rituximab prescription for ANCA-associated necrotizing vasculitides justifies the publication of recommendations for clinicians. Rituximab is approved in the United States to induce and maintain remission. In Europe, rituximab was recently approved for remission induction. However, governmental agencies’ approvals cannot replace clinical practice guidelines. Herein, the French Vasculitis Study Group Recommendations Committee, comprised of physicians with extensive experience in the treatment of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience.

Résumé

L’utilisation grandissante du rituximab en traitement des vascularites nécrosantes associées aux ANCA justifie la publication de recommandations de pratiques. Une autorisation de mise sur le marché (AMM) a été obtenue aux États-Unis d’Amérique pour l’induction et le maintien de la rémission et en Europe pour l’induction de la rémission. Ces autorisations ne se substituent pas aux règles de bonne pratique clinique et le groupe d’expert réuni par le Groupe français d’étude des vascularites présente ici une liste de recommandations fondées sur l’analyse de la littérature, les résultats d’études thérapeutiques prospectives et le consensus établi par des médecins du groupe.

Section snippets

References (51)

  • L.D. Kaplan et al.

    Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS–Malignancies Consortium Trial 010

    Blood

    (2005)
  • S. Van Assen et al.

    Vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

    Autoimmune Review

    (2011)
  • J.H. Stone et al.

    Rituximab versus cyclophosphamide for ANCA-associated vasculitis

    N Engl J Med

    (2010)
  • R.B. Jones et al.

    Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

    N Engl J Med

    (2010)
  • P. Charles et al.

    Rituximab for induction and maintenance treatment of ANCA-associated vasculitides. A multicenter retrospective study on 80 patients

    Rheumatology (Oxford)

    (2013)
  • J.C. Jennette et al.

    2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides

    Arthritis Rheum

    (2013)
  • D.T. Boumpas et al.

    Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

    Ann Intern Med

    (1993)
  • Procédure Nationale de Soins : vascularites....
  • J.U. Holle et al.

    Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations

    Ann Rheum Dis

    (2012)
  • L. Guillevin et al.

    The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort

    Medicine (Baltimore)

    (2011)
  • K.K. Dønvik et al.

    Churg–Strauss syndrome treated successfully with rituximab

    Rheumatol Int

    (2011)
  • R. Cartin-Ceba et al.

    Rituximab for the treatment of Churg–Strauss syndrome with renal involvement

    Nephrol Dial Transplant

    (2011)
  • J. Saech et al.

    Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement

    Ann Rheum Dis

    (2010)
  • D. Roccatello et al.

    Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement

    Clin Exp Rheumatol

    (2008)
  • R.J. Pepper et al.

    Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production

    Rheumatology (Oxford)

    (2008)
  • Cited by (66)

    • ANCA associated vasculitis

      2020, European Journal of Internal Medicine
      Citation Excerpt :

      HIV, HCV and HBV serology should be requested prior to its use. RTX may be used in HIV patients with CD4>50 [83,84] and with HCV infection [79]. In HBsAg and/or anti-HBc positive patients, prior or concurrently with RTX, entecavir/tenofovir must be initiated.

    View all citing articles on Scopus
    1

    French Vasculitis Study Group (www.vascularites.org).

    View full text